细胞治疗在遗传性肺泡蛋白沉积症中的研究进展  

Research progress of cell therapy in hereditary pulmonary alveolar proteinosis

作　　者：张梦妮 金晶 宋新宇 李时悦 Zhang Mengni;Jin Jing;Song Xinyu;Li Shiyue(The First affiliated hospital of Guangzhou Medical University,Guangzhou Institute of Respiratory Health,Guangdong Provincial Key Laboratory of Vascular Diseases,The National Center for Respiratory Medicine,State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou 510120,China;School of Clinical Medicine,Henan University)

机构地区：[1]广州呼吸健康研究院、呼吸疾病国家重点实验室、广州医科大学附属第一医院、国家呼吸医学中心,广州510120 [2]河南大学临床医学院

出　　处：《中华结核和呼吸杂志》2023年第7期730-734,共5页Chinese Journal of Tuberculosis and Respiratory Diseases

摘　　要：遗传性肺泡蛋白沉积症(hPAP)是一种罕见的间质性肺疾病,由CSF2RA或CSF2RB突变引起,其特征为肺泡巨噬细胞功能失衡引起表面活性物质沉积。全肺灌洗治疗可有效缓解症状,但具有一定风险。细胞治疗是一种新型治疗方法,已在hPAP治疗中取得进展,为hPAP的治疗提供了新的治疗策略。Hereditary pulmonary alveolar proteinosis(hPAP)is a rare interstitial lung disease caused by mutation in CSF2RA/CSF2RB,characterized by the deposition of pulmonary surfactant due to the alveolar macrophage dysfunction.The whole lung lavage can effectively alleviate the symptoms but is associated with potential complications.Cell therapy is a novel approach with advances that provide a new therapeutic strategy for the treatment of hPAP.

关 键 词：肺泡蛋白沉积症 间质性肺疾病 表面活性物质 细胞治疗 治疗策略 新型治疗方法 全肺灌洗治疗 缓解症状 

分 类 号：R563[医药卫生—呼吸系统]